ERISEris Lifesciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ERIS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 200.0% YoY
- • ROE: 18.1%
- • Debt/Equity: 0.61
- • RSI: 57
- • MACD: fresh bullish crossover
- • Price vs EMA21: above
Bull case
- • Profit growth: 200.0% YoY
- • ROE: 18.1%
- • Debt/Equity: 0.61
- • RSI: 57
Bear case
- • Revenue growth: 7.1% YoY
- • Dividend yield: 0.49%
- • Golden cross setup: SMA50 below SMA200
- • Trend strength (ADX): 15
Key risks
- • Revenue growth: 7.1% YoY
- • Dividend yield: 0.49%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹41.11). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.